高级检索
当前位置: 首页 > 详情页

GATA1-Activated HNF1A-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-32-5p to Upregulate RNF38

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]First Peoples Hosp Yunnan Prov, Dept Breast Thyroid Surg, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China
出处:
ISSN:

关键词: HNF1A-AS1 miR-32-5p RNF38 triple-negative breast cancer

摘要:
Background: Triple-negative breast cancer (TNBC) is a highly invasive subtype of breast cancer with a high mortality rate. Recently, long non-coding RNAs (lncRNAs) are confirmed to modulate the progression of assorted cancers, including TNBC. However, the functions of lncRNA HNF1 homeobox A antisense RNA 1 (HNF1A-AS1) in TNBC are still unclear. Aim: We aimed to investigate the function and mechanism of HNF1A-AS1 in TNBC. Methods: The expression of genes in TNBC cells was tested by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. In vitro loss-of-function assays and in vivo xenograft experiments were conducted for evaluating the impact of HNF1A-AS1 on TNBC progression. RNA pull-down, luciferase reporter and RNA immunoprecipitation (RIP) assays were utilized for assessing the correlations between molecules. Results: We discovered that HNF1A-AS1 was highly expressed in TNBC tissues and cells. Knockdown of HNF1A-AS1 restrained cell proliferation but accelerated cell apoptosis. Besides, GATA-binding protein 1 (GATA1) activated HNF1A-AS1 transcription in TNBC. MicroRNA-32-5p (miR-32-5p) was slowly expressed in TNBC cells and sponged by HNF1A-AS1, and its overexpression hinders TNBC cell growth. Ring finger protein 38 (RNF38) was verified as the target of miR-32-5p, and HNF1A-AS1 was a competing endogenous RNA (ceRNA) of RNF38 through sponging miR-32-5p. Rescue experiments indicated that upregulation of RNF38 reversed the inhibited impacts of silencing HNF1AAS1 on TNBC cell growth. Conclusion: GATA1-activated HNF1A-AS1 facilitated TNBC progression via miR-32-5p/ RNF38 axis. The findings may provide new roads for developing targeted therapies of TNBC.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q3 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]First Peoples Hosp Yunnan Prov, Dept Breast Thyroid Surg, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [*1]Department of Breast Thyroid Surgery, The First People’s Hospital of Yunnan Province, No. 157 Jinbi Road, Kunming, 650032, People’s Republic of China
通讯作者:
通讯机构: [1]First Peoples Hosp Yunnan Prov, Dept Breast Thyroid Surg, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [*1]Department of Breast Thyroid Surgery, The First People’s Hospital of Yunnan Province, No. 157 Jinbi Road, Kunming, 650032, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:87481 今日访问量:0 总访问量:721 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号